SCHEMBL3504140

SCHEMBL3504140

COc1cc2c(cc1O)CN(CCc1ccccc1)CC2

nearest known ligand 0.79

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
DHCR7 Q9UBM7 3/20 0.79
ABCB1 P08183 8/20 0.62
ABCG2 Q9UNQ0 4/20 0.62
CA2 P00918 1/20 0.60
CA9 Q16790 1/20 0.60
KDM4E B2RXH2 1/20 0.58
TDP1 Q9NUW8 1/20 0.58
DRD2 P14416 1/20 0.57
DRD1 P21728 1/20 0.57
DRD4 P21917 1/20 0.57
DRD3 P35462 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13896162 0.91 ABCB1 (0.73) DHCR7ABCB1ABCG2
SCHEMBL3042454 0.89 DHCR7 (0.81) DHCR7ABCB1ABCG2CA2CA9
SCHEMBL14739911 0.89 DHCR7 (1.00) DHCR7ABCB1CA2CA9KDM4E
SCHEMBL14740411 0.88 DHCR7 (0.79) DHCR7ABCB1ABCG2CA2CA9
SCHEMBL17664977 0.88 DHCR7 (0.79) DHCR7ABCB1ABCG2CA2CA9
SCHEMBL14330769 0.88 DHCR7 (0.79) DHCR7ABCB1ABCG2CA2CA9
SCHEMBL14739580 0.88 DHCR7 (1.00) DHCR7ABCB1ABCG2CA2CA9
SCHEMBL3051392 0.88 CA2 (0.73) DHCR7ABCB1ABCG2CA2CA9
SCHEMBL3506177 0.88 CA2 (0.73) DHCR7ABCB1ABCG2CA2CA9
SCHEMBL14739655 0.88 DHCR7 (0.78) DHCR7ABCB1ABCG2CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3589626-B1 8-PHENYL-ISOQUINOLINES AND PHARMACEUTICAL COMPOSITION THEREOF USED IN THE TREATMENT OF IRRITABLE BOWEL SYNDROME UNIV NAT TAIWAN (TW) 2024-06-12 EP disclosed
US-20200071274-A1 8-PHENYL-ISOQUINOLINES AND PHARMACEUTICAL COMPOSITION THEREOF USED IN THE TREATMENT OF IRRITABLE BOWEL SYNDROME NATIONAL TAIWAN UNIVERSITY (TW) 2020-03-05 US disclosed
US-20200071274-A1 8-PHENYL-ISOQUINOLINES AND PHARMACEUTICAL COMPOSITION THEREOF USED IN THE TREATMENT OF IRRITABLE BOWEL SYNDROME NATIONAL TAIWAN UNIVERSITY (TW) 2020-03-05 US disclosed
US-8552028-B2 8-phenylisoquinolines and pharmaceutical composition used in treatment for sepsis NATIONAL TAIWAN UNIVERSITY (TW) 2013-10-08 US disclosed
US-20100217003-A1 1,2,3,4-TETRAHYDROISOQUINOLINE DERIVATIVES HAVING EFFECTS OF PREVENTING AND TREATING DEGENERATIVE AND INFLAMMATORY DISEASES UNIVERSITY OF ULSAN FOUNDATION FOR INDUSTRY COOPERATION (KR) 2010-08-26 US disclosed
EP-2117547-A1 1,2,3,4-TETRAHYDROISOQUINOLINE DERIVATIVES HAVING EFFECTS OF PREVENTING AND TREATING DEGENERATIVE AND INFLAMMATORY DISEASES University Of Ulsan Foundation For Industry Cooperation (KR) 2009-11-18 EP disclosed
WO-2008069632-A1 1,2,3,4-TETRAHYDROISOQUINOLINE DERIVATIVES HAVING EFFECTS OF PREVENTING AND TREATING DEGENERATIVE AND INFLAMMATORY DISEASES UNIVERSITY OF ULSAN FOUNDATION FOR INDUSTRY COOPERATION (KR) 2008-06-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100217003-A1 1,2,3,4-TETRAHYDROISOQUINOLINE DERIVATIVES HAVING EFFECTS OF PREVENTING AND TREATING DEGENERATIVE AND INFLAMMATORY DISEASES NFKBIA, HMOX1, PTGS1 DHCR7 1625/4885ABCB1 1589/4885ABCG2 4794/4885
US-20200071274-A1 8-PHENYL-ISOQUINOLINES AND PHARMACEUTICAL COMPOSITION THEREOF USED IN THE TREATMENT OF IRRITABLE BOWEL SYNDROME HTR7, GPR27, HTR5A DHCR7 1398/4885ABCB1 328/4885ABCG2 136/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.